优质护理对卵巢癌手术患者的临床效果观察

探讨优质护理对卵巢癌手术患者的临床效果。方法:将我院2019年1月-2020年1月80例卵巢癌手术患者,数字表随机法分二组。对照组给予常规护理,优质护理组实施优质护理。比较满意度、癌因性疲乏程度评分。结果:优质护理组的护理满意度比对照组高(P<0.05)。优质护理组的癌因性疲乏程度评分比对照组低(P<0.05)。结论:卵巢癌手术患者实施优质护理效果确切,可减轻患者癌因性疲乏,提高满意度。

卵巢癌手术患者优质护理服务的应用效果研究

研究卵巢癌手术患者优质护理服务的应用效果。方法:选取我院2015 年3 月到2016 年3 月期间收治的卵巢癌手术患者20 例,将其随机均分为对照组和试验组。对照组患者采用常规护理方式,试验组采用优质护理服务方式,比较两组患者治疗效果、住院时间、保护两反应发生情况和满意度。结果:试验组患者住院时间、术后并发症发生率明显低于对照组,两组数据相比差异具有统计学意义(p<0.05)。并且试验组患者满意度明显高于对照组,两组数据相比差异具有统计学意义(P<0.05)。结论:卵巢癌手术患者使用优质护理服务能够有效提升患者治疗效果,减少患者住院时间,降低患者不良反应发生率,并且能明显提升患者满意度,具有很高临床推广价值。

优质护理干预对卵巢癌手术患者负性情绪的影响分析

对优质护理干预对卵巢癌手术患者负性情绪是否产生影响进行研究论证,为卵巢癌患者的临床护理及围手术期护理提供参考依据。方法:选择患有卵巢癌并且即将手术的70例患者,根据入院的先后顺序平均分组,先入院的35例患者在常规护理模式下接受手术(常规组),后入院的35例患者在优质护理干预下手术(优质组),以患者术后的SAS及SDS评分判定护理干预对患者负性情绪的影响,并对两组患者的护理满意率进行统计和比较。结果:优质组患者干预后的SAS、SDS评分低于常规组(P<0.05),护理满意率高于常规组(P<0.05)。结论:给予卵巢癌手术患者优质护理干预,充分满足患者心理需求,对于改善其负性情绪,提高治疗依从性具有重要意义,患者反馈良好,对护理工作给出了较高评价。

Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation

Objective： To investigate the clinical efficacy of intraperitoneal chemotherapy before surgery for ovarian cancer. Methods： 60 patients with stages Ⅱ-Ⅳ of ovarian cancer were treated with intraperitoneal chemotherapy of CAP or TP regimen followed by a surgery treatment and another chemotherapy for 6 cycles. And then the efficiency of the therapy was evaluated by analyzing the changes of ascites, the serum CA-125 and CA-19-9 levels and the findings in the operation, and investigating the recurrence of cancer and the survival. Results： After 1-3 cycles of intraperitoneal chemotherapy, serum levels of CA-125 and CA-19-9 and carcinous ascites significantly reduced in all patients, ascites reduce was over 50% in 98.3% cases; all cases were successfully treated with cytoreduction and it was found during the operation that bulky tumor was reduced and looser so as to be easily isolated and removed; PFS of the patients was prolonged, while the toxicity and side-effects were not so serious as beyond the patient toleration. Conclusion： Intraperitoneal chemotherapy before surgery for ovarian cancer has an active efficacy in clinic, being able to improve conditions of surgery and increase the opportunity of maximal cytoreduction, and prolong survival of the patients, and should be a good selection for the treatment of advanced ovarian cancer.